{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:18:57Z","timestamp":1648721937908},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1080\/13693780600902235","type":"journal-article","created":{"date-parts":[[2006,8,30]],"date-time":"2006-08-30T03:00:09Z","timestamp":1156906809000},"page":"S309-S314","source":"Crossref","is-referenced-by-count":0,"title":["The debate: The trials have told us very little"],"prefix":"10.1093","volume":"44","author":[{"given":"Archie G","family":"Prentice","sequence":"first","affiliation":[{"name":"Royal Free Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,9]]},"reference":[{"key":"key\n\t\t\t\t2018110606154899100_b1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b3","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.1987.5.12.1985","article-title":"Favourable outcome of invasive aspergillosis in patients with acute leukaemia","volume":"5","author":"Burch","year":"1987","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154899100_b4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005792-199805000-00004","article-title":"Invasive aspergillosis. Clinical features of 35 proven cases at a single institution","volume":"77","author":"Kaiser","year":"1987","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2018110606154899100_b5","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01739009","article-title":"Amphotericin B versus Amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients","volume":"22","author":"Verweij","year":"1994","journal-title":"Infection"},{"key":"key\n\t\t\t\t2018110606154899100_b6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01967060","article-title":"Fungal infections in cancer patients: An international autopsy survey","volume":"11","author":"Bodey","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b7","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinte.1991.00400040107024","article-title":"Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study","volume":"151","author":"Walsh","year":"1991","journal-title":"Arch Int Med"},{"key":"key\n\t\t\t\t2018110606154899100_b8","first-page":"171","article-title":"tude multicentrique randomisee fluconazole IV versus amphot\u00e9ricine B IV chez le patient neutrop\u00e9nique et f\u00e9brile","volume":"2","author":"Marie","year":"1993","journal-title":"Cahiers Oncol"},{"key":"key\n\t\t\t\t2018110606154899100_b9","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0959-8049(95)00619-2","article-title":"Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial","volume":"32","author":"Viscoli","year":"1996","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2018110606154899100_b10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0163-4453(95)80009-3","article-title":"Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever \u2013 preliminary observations from a pilot, exploratory study","volume":"30","author":"Ellis","year":"1995","journal-title":"J Infect"},{"key":"key\n\t\t\t\t2018110606154899100_b12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0002-9343(98)00326-X","article-title":"A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia","volume":"105","author":"Malik","year":"1998","journal-title":"Am J Med"},{"issue":"Suppl. 2","key":"key\n\t\t\t\t2018110606154899100_b13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1439-0507.1999.tb00023.x","article-title":"Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B\/flucytosine","volume":"42","author":"Silling","year":"1999","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t2018110606154899100_b14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.7326\/0003-4819-135-6-200109180-00010","article-title":"Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial","volume":"135","author":"Boogaerts","year":"2001","journal-title":"Ann Int Med"},{"issue":"(Suppl.)","key":"key\n\t\t\t\t2018110606154899100_b15","first-page":"42b","article-title":"Intravenous itraconazole followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients","volume":"100","author":"Ehninger","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018110606154899100_b16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2018110606154899100_b17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of Amphotericin B colloidal dispersion vs. Amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b21","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b22","doi-asserted-by":"crossref","first-page":"59a","DOI":"10.1182\/blood.V104.11.192.192","article-title":"PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: preliminary results of a prospective study","volume":"104","author":"Hebart","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018110606154899100_b23","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prosepective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b25","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1086\/515033","article-title":"An EORTC international randomised trial comparing two doses of liposomal amphotericin B for treatment of invasive aspergillosis","volume":"27","author":"Ellis","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal Amphotericin B compared with Amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2018110606154899100_b27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018110606154899100_b28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b29","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation \u2013 a prospective, randomised, double-blind study","volume":"171","author":"Slavin","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2018110606154899100_b30","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/1097-0142(20001001)89:7<1611::AID-CNCR27>3.0.CO;2-B","article-title":"Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials","volume":"89","author":"Kanda","year":"2000","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018110606154899100_b31","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018110606154899100_b32","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018110606154899100_b33","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/cncr.10610","article-title":"Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials","volume":"94","author":"Bow","year":"2002","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2018110606154899100_b34","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1200\/JCO.2003.04.052","article-title":"Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: evidence from a meta-analysis of 3,597 patients","volume":"21","author":"Glasmacher","year":"2003","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2018110606154899100_b35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/sj.bmt.1700737","article-title":"Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients","volume":"19","author":"Jantunen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"key\n\t\t\t\t2018110606154899100_b36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03259.x","article-title":"Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients","volume":"116","author":"Martino","year":"2002","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2018110606154899100_b37","volume-title":"Posaconazole versus fluconazole for prophylaxis of invasive fungal infection allogeneic stem cell transplant recipients with graft-versus-host-disease: results of a multicentre trial","author":"Ullmann","year":"2005"},{"key":"key\n\t\t\t\t2018110606154899100_b38","doi-asserted-by":"crossref","first-page":"524a","DOI":"10.1182\/blood.V106.11.1844.1844","article-title":"Posaconazole versus standard azole (flu\/itra) therapy for prophylaxis of invasive fungal infections among high risk neutropenic patients: results of a randomised multicentre trial","volume":"106","author":"Cornely","year":"2005","journal-title":"Blood"},{"key":"key\n\t\t\t\t2018110606154899100_b39","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/44\/Supplement_1\/S309\/26367840\/44-supplement_1-s309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T02:52:44Z","timestamp":1587178364000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/44\/Supplement_1\/S309\/1747547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,1]]},"references-count":39,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2006,9]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1080\/13693780600902235","relation":{},"ISSN":["1460-2709","1369-3786"],"issn-type":[{"value":"1460-2709","type":"electronic"},{"value":"1369-3786","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,9]]},"published":{"date-parts":[[2006,9,1]]}}}